10-Q: Lifeward Ltd. Reports Strong Revenue Growth in Q3 2024, Streamlines Operations

Lifeward Ltd. saw a significant increase in revenue in the third quarter of 2024, driven by expanded Medicare coverage and the integration of AlterG, while also announcing a streamlining of US operations.

Summary

• Lifeward Ltd. reported a 39% increase in revenue for the third quarter of 2024, reaching $6.1 million, compared to $4.4 million in the same period last year.
• The revenue growth was primarily driven by increased sales of ReWalk systems due to expanded Medicare coverage, stronger sales in Germany, and the inclusion of AlterG sales.
• For the nine months ended September 30, 2024, revenue increased by $11.1 million to $18.1 million, compared to $6.97 million in the same period of 2023.
• The company's gross profit margin for the third quarter was 36.2%, compared to 19.6% in the same period last year, with a 35.2% gross profit margin for the nine months ended September 30, 2024.
• Lifeward is streamlining its U.S. operations by closing two facilities, which is expected to save approximately $3 million in operating expenses and improve gross margins by about two percentage points.
• The company's net loss for the third quarter was $3.1 million, or $0.35 per share, compared to a net loss of $7.5 million, or $0.88 per share, in the same period last year.
• The net loss for the nine months ended September 30, 2024 was $13.7 million, or $1.58 per share, compared to a net loss of $16.5 million, or $1.94 per share, in the same period last year.
• As of September 30, 2024, the company had $10.7 million in cash and cash equivalents and a negative operating cash flow of $17.7 million for the nine months ended September 30, 2024.
• The company believes it has sufficient funds to support its operations for more than 12 months following the issuance date of its unaudited condensed consolidated financial statements for the nine months ended September 30, 2024.

Sentiment

Score: 7

Explanation: The document shows positive revenue growth and cost-cutting measures, but the company is still operating at a loss and needs to raise capital. The sentiment is cautiously optimistic.

Positives

• Significant revenue growth driven by Medicare coverage expansion and AlterG acquisition.
• Improved gross profit margins compared to the previous year.
• Cost-saving measures through streamlining U.S. operations.
• Successful launch of the AlterG NEO product.
• Strengthened board with the addition of a new director and audit committee chair.
• Reduced net loss per share compared to the same period last year.

Negatives

• The company continues to experience net losses.
• Negative operating cash flow for the nine months ended September 30, 2024.
• Gross profit margin decreased slightly when excluding acquisition-related charges.
• Research and development expenses increased for the nine months ended September 30, 2024.

Risks

• The company's transition to profitability is dependent on successful product commercialization and reimbursement.
• The company may need to raise additional capital to fund future operations.
• The company is subject to limitations under Form S-3 rules, which may constrain its ability to secure capital.
• The company is exposed to market risks, including the impact of inflation and global instability.
• The company is dependent on a single contract manufacturer for some of its products.
• The company is subject to legal claims and regulatory risks.

Future Outlook

The company expects future growth to be driven by sales of the ReWalk Personal device through expanded coverage and reimbursement, as well as sales of AlterG anti-gravity systems and distributed products. The company also anticipates increased gross profit margins as revenue volumes increase and operating efficiencies are realized. The company expects to incur future net losses and its transition to profitability is dependent upon, among other things, the successful development and commercialization of its products and product candidates, the establishment of contracts for the distribution of new product lines, or the acquisition of additional product lines.

Management Comments

• Lifeward initiated actions to further streamline its U.S. operations including closing two U.S. facilities to complete the integration of AlterG.
• Lifeward began selling the AlterG family of products through its German sales organization.
• Lifeward executed a successful launch of the AlterG NEO.
• Lifeward completed its near-term plans to refresh its Board of Directors with the addition of Robert J. Marshall Jr.

Industry Context

The company's focus on expanding Medicare coverage for its ReWalk Personal Exoskeleton aligns with the broader trend of increasing reimbursement for advanced medical technologies. The acquisition of AlterG and the launch of the NEO product demonstrate a strategic move to diversify product offerings and address a wider range of rehabilitation needs. The streamlining of operations reflects a common industry practice of optimizing resources and reducing costs to achieve profitability.

Comparison to Industry Standards

• Lifeward's revenue growth of 39% in Q3 2024 is strong compared to the average growth rate of medical device companies, which typically ranges from 5% to 15% annually.
• The company's gross profit margin of 36.2% is within the typical range for medical device companies, but there is room for improvement to reach the higher end of the industry average of 40% to 60%.
• The company's operating loss of $3.2 million in Q3 2024 is not uncommon for companies in the growth phase, but the company will need to demonstrate a clear path to profitability to attract long-term investors.
• The company's cash position of $10.7 million is relatively low compared to other medical device companies, which typically maintain a cash balance of at least 12 months of operating expenses.
• The company's streamlining of operations is a common practice in the medical device industry to reduce costs and improve efficiency, similar to actions taken by companies like Medtronic and Stryker.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the company's revenue growth and cost-cutting measures.
• Employees may be affected by the streamlining of U.S. operations.
• Customers will benefit from the company's expanded product offerings and improved access to reimbursement.
• Suppliers may be affected by the company's move to a contract manufacturer for AlterG products.
• Creditors may be affected by the company's need to raise additional capital.

Next Steps

• Continue to focus on sales, marketing, and reimbursement efforts for ReWalk and AlterG products.
• Advance product development activities for AlterG Anti-Gravity systems.
• Prepare for the next stages following the recent FDA 510(k) submission for clearance of the ReWalk 7.
• Complete the integration of AlterG and streamline U.S. operations.
• Monitor and manage cash flow and explore additional funding options.

Key Dates

Keywords

ReWalk, exoskeleton, AlterG, Medicare, rehabilitation, revenue growth, gross profit, cost reduction, medical device, operating expenses